Bone Metastasis and Hormone Therapy
نویسندگان
چکیده
منابع مشابه
Transdermal hormone therapy and bone health
The clinical aftermath of the reporting of the initial findings of the Women's Health Initiative (WHI) in 2002 was a profound reduction in the use of hormone therapies by menopausal women. This reduction led to a well documented increase in vasomotor symptoms and vaginal atrophy among those women who discontinued their hormone regimens. However, another adverse impact among these women, as well...
متن کامل[Molecular basis of bone metastasis formation and its targeted therapy].
Formation of bone metastasis is a hallmark of the progression of several solid cancers, providing example for the organ specificity of the process. Bone metastasis may result in both venous and arterial dissemination. Though the molecular basis of the lytic and plastic bone metastasis formation is different, in reality these organ metastases represent a mixture of the two processes. The basis o...
متن کاملDLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.
Bone metastasis is a frequent complication of breast cancer that is often accelerated by TGF-β signaling; however, little is known about how the TGF-β pathway is regulated during bone metastasis. Here we report that deleted in liver cancer 1 (DLC1) is an important regulator of TGF-β responses and osteolytic metastasis of breast cancer cells. In murine models, breast cancer cells lacking DLC1 ex...
متن کاملBone metastasis and rehabilitation.
Patients with cancer that has metastasized to bone will frequently develop functional problems that may respond to rehabilitative treatment. Many rehabilitation professionals, however, are concerned about the possibility of producing pathologic fracture with their treatment. Several methods have been proposed for identifying which malignant lesions in bone are at risk of fracture. In this artic...
متن کاملPhysician preferences for bone metastasis drug therapy in Canada.
BACKGROUND Currently in Canada, several bone-targeted agents (btas) with varying characteristics are available for the prevention of skeletal-related events (sres) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available btas. METHODS Physicians treating patients with bon...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orthopedics & Traumatology
سال: 1968
ISSN: 1349-4333,0037-1033
DOI: 10.5035/nishiseisai.18.1